{"id":18736,"date":"2026-06-10T13:00:00","date_gmt":"2026-06-10T11:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=756645abf9069f94f994947eef1ac24b"},"modified":"2026-06-10T13:00:00","modified_gmt":"2026-06-10T11:00:00","slug":"meridian-bioscience-and-4bases-announce-collaboration-to-enable-rapid-globally-scalable-next-generation-sequencing-workflows","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=18736","title":{"rendered":"Meridian Bioscience and 4bases Announce Collaboration to Enable Rapid, Globally Scalable Next-Generation Sequencing Workflows"},"content":{"rendered":"

\nAmbient-stable NGS workflows, enabled by Meridian\u2019s lyophilization expertise, expand global access to 4bases\u2019 KaryoSolver\u2122*, a platform for rapid structural variant analysis<\/p><\/a><\/a>

CINCINNATI--(BUSINESS WIRE)--The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced a collaboration with 4bases SA to support the global deployment of KaryoSolver, a next-generation cytogenetics assay, through advanced assay stabilization.<\/p>

\nKaryoSolver represents a significant step forward in cytogenetics. Traditional workflows rely on multiple complementary tests, often taking days to deliver a complete picture. In contrast, KaryoSolver consolidates structural variant detection into a single assay with integrated data analysis, providing actionable genomic insights within hours.<\/p>

\nHowever, bringing this innovation to a global market requires overcoming a critical barrier: reagent stability. Conventional liquid-based NGS library preparation solutions are inherently limited by short shelf life, creating significant challenges across the distribution chain, including the cost and complexity of refrigerated shipping and storage that have historically restricted scalable global expansion.<\/p>

\nMeridian addressed this challenge through its advanced reagent stabilization platform, combining formulation science with optimized enzyme lyophilization technology. By stabilizing the NGS library preparation components, Meridian enabled KaryoSolver to be shipped and stored at ambient temperatures, eliminating cold-chain requirements, extending shelf life, and simplifying inventory management across the global distribution channels. In addition, lyophilization streamlines manufacturing, supporting more efficient and scalable production.<\/p>

\n\u201cOur platform technology enabled the transition of the assay into a room-temperature stable format while preserving the performance characteristics required for molecular diagnostics,\u201d said Florent Chang-Pi-Hin, Vice President, Research and Development at Meridian Life Science. \u201cBy removing cold-chain constraints without sacrificing assay integrity, we\u2019re helping expand access to reliable testing worldwide.\u201d<\/p>

\nIn this collaboration, Meridian and 4bases R&D teams joined efforts to integrate Meridian\u2019s stabilized NGS library preparation chemistries into 4bases\u2019 Oxford Nanopore Technologies workflow.<\/p>

\n\u201cThe idea behind KaryoSolver is to simplify access to comprehensive genetic diagnosis, and Meridian\u2019s expertise in stabilization has been transformative,\u201d said Fabio Grandi, COO & Co-Founder at 4bases. \u201cShort shelf life and cold-chain requirements previously limited how far and how efficiently we could scale. With lyophilization, we can now reliably supply our global customers while simplifying logistics, reducing costs, and accelerating the adoption of KaryoSolver as a rapid, single-workflow solution for cytogenetics.\u201d<\/p>

\nTogether, Meridian and 4bases are removing key barriers to advanced genomic testing, pairing breakthrough assay design with the stability, scalability, and operational efficiency required for effective global deployment.<\/p>

\n4bases and Meridian Bioscience will both be exhibiting at the upcoming European Human Genetics Conference (ESHG) on June 13\u201316 in Gothenburg, Sweden, where attendees will have the opportunity to learn more about the companies\u2019 collaboration and latest advances in ambient-stable next-generation sequencing workflows and cytogenetics solutions. Additional event details, including opportunities to schedule meetings with the Meridian Bioscience and 4bases\u2019 teams during ESHG, can be found on Meridian Life Science\u2019s events page<\/a> and on 4bases\u2019 website<\/a>.<\/p>

\nMeridian Bioscience will also be exhibiting at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) 2026 meeting, taking place July 26-30 in Anaheim, California, where the company will showcase its broader molecular diagnostics and next-generation sequencing portfolio, including solutions designed to support ambient-stable assay development and workflow optimization.<\/p>

\nFor more information on Meridian\u2019s ambient-stable solutions and services, please visit https:\/\/www.meridianbioscience.com\/lifescience\/products\/molecular-reagents\/services\/<\/a><\/p>

\nAbout Meridian Bioscience, Inc.<\/b><\/p>

\nMeridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that provide answers with speed, accuracy, and simplicity, redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian is a privately held company headquartered in Cincinnati, Ohio. Meridian\u2019s website address is www.meridianbioscience.com.<\/a><\/p>

\nAbout 4bases SA<\/b><\/p>

\n4bases SA is a Swiss biotechnology company specializing in the development and production of clinically validated, CE-IVD genetic diagnostic solutions for precision medicine. The company offers platform-independent next-generation sequencing (NGS) reagent kits, data analysis software, and diagnostic protocols designed to support healthcare professionals in delivering accurate and actionable genetic insights.<\/p>

\nThrough its integrated solutions, including proprietary analysis platforms and Oxford Nanopore-compatible workflows, 4bases enables comprehensive genomic analysis for applications such as hereditary disease, oncology, and cytogenetics. The company is committed to delivering high-quality, scalable technologies that improve diagnostic efficiency and patient outcomes worldwide. 4bases\u2019 web address is www.4bases.ch.<\/a><\/p>

\n*KaryoSolver\u2122 is a trademark of 4bases and used with permission.<\/p> Contacts<\/b>

\nBen Hahlen\nDirector of Product Management and Downstream Marketing Meridian Bioscience, Inc.\nPhone: 513.991.1091\nEmail: info@meridianbioscience.com<\/a>\nSabrina Prada\nDirector of Communications 4bases SA\nPhone: +41 91 610 04 20\nEmail: sabrina.prada@4bases.ch<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Ambient-stable NGS workflows, enabled by Meridian\u2019s lyophilization expertise, expand global access to 4bases\u2019 KaryoSolver\u2122*, a platform for rapid structural variant analysisCINCINNATI–(BUSINESS WIRE)–The Life Science division of Meridian Bioscience,…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18736","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18736"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18736\/revisions"}],"predecessor-version":[{"id":18737,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/18736\/revisions\/18737"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}